A recent retrospective study revealed that the progression-free survival (PFS) after allo-HSCT for SM-AML is only 0.7 years (13).The absence of a KIT D816V mutation adversely affected PFS post allo-HSCT. This evidence concerns the gene KIT and acute myeloid leukemia.